Q:

Over the past two years, many QC laboratories and CDMOs have reported rising rates of analytical method transfer failures, even for widely used chromatographic and compendial methods. What is driving this trend, and what can laboratories do to prevent method transfer setbacks?

A:

Method transfer failures have become more common due to a combination of instrument variation, inadequate system suitability criteria, insufficient method robustness, and gaps in analytical lifecycle management. While these issues are not new, recent FDA inspection trends show that analytical variability especially between different laboratory sites has emerged as a major contributor to OOS investigations and delayed batch release¹.

One underlying factor is the industry-wide shift toward complex modalities such as peptides, oligonucleotides, and lipid nanoparticles, which are more sensitive to chromatographic and sample-handling variables. In addition, ICH Q14 and the updated Q2(R2) guidelines emphasize the need for scientifically justified method development with formal robustness assessments, something many legacy methods lack².

Another driver is the rise of non-equivalent instrumentation. Two HPLCs may meet the same performance specifications, but differences in dwell volume, gradient delay, detector bandwidth, and column lot variability can cause retention shifts or peak distortion—especially in gradient methods. USP General Chapter <1224> specifically warns that method transfer must consider system differences, not just execution steps³.

What can labs do? Current best practices include:

• Conducting formal robustness studies during method development rather than relying solely on system suitability.
• Using risk-based method transfer protocols aligned with ICH Q14 lifecycle principles.
• Evaluating chromatographic system parameters such as dwell volume, pump mixing, and gradient performance as part of transfer readiness.
• Including side-by-side comparison studies and pre-transfer system checks to identify variability drivers.
• Maintaining strong data integrity controls, since inconsistent raw data recording is one of the most common FDA findings in analytical method investigations.

As regulators shift toward lifecycle-driven analytical models, laboratories that adopt stronger method robustness strategies and deeper equipment characterization will see fewer transfer failures and smoother technical handoffs.

---

References

---

Footnotes

1. U.S. Food and Drug Administration. Inspection Observations (Form 483) Data. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-observations ↩
2. International Council for Harmonisation (ICH). Q2(R2) Validation of Analytical Procedures and Q14 Analytical Procedure Development. https://www.ich.org ↩
3. United States Pharmacopeia (USP). General Chapter <1224>: Transfer of Analytical Procedures. https://www.usp.org ↩